Dear Doctor Letter (Rote-Hand-Brief) on hydrochlorothiazide: risk of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma)
2018.10.17
Active substance: hydrochlorothiazide
Marketing authorisation holders of the products containing hydrochlorothiazide would like to inform about pharmacoepidemiological studies which have shown a risk of non-melanoma skin cancer (NMSC) (basal cell carcinoma, squamous cell carcinoma) with exposure to increasing cumulative doses of hydrochlorothiazide (HCTZ).
Download DHPC/Information letter , Download_VeroeffentlichtAm_EN